Filament Health signs UC San Francisco phase 2 psilocybin trial license
Rhelion Life Sciences says its wholly owned subsidiary Filament Health signed a licence agreement with the University of California, San Francisco for a Phase 2 trial of psilocybin in methamphetamine use disorder among people with HIV.
Story updates
12:21:34 PM UTC
SquawkNews
Rhelion’s subsidiary Filament signed a licence and supply deal with UCSF to provide PEX010 (25 mg and 5 mg) for a Phase 2 psilocybin trial in methamphetamine use disorder among people with HIV, expected to start November 2026. Filament is not the trial sponsor.Material DetailsContext by AI AnalystT…